Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

@article{Buck2006RapamycinSW,
  title={Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.},
  author={Elizabeth Buck and Alexandra Eyzaguirre and Eric J. Brown and Filippo Petti and Siobhan McCormack and John D. Haley and Kenneth K. Iwata and Neil W. Gibson and Graeme Griffin},
  journal={Molecular cancer therapeutics},
  year={2006},
  volume={5 11},
  pages={2676-84}
}
The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers. One important signaling pathway regulated by EGFR is the phosphatidylinositol 3'-kinase (PI3K)-phosphoinositide-dependent kinase 1-Akt pathway. Activation of Akt leads to the stimulation of antiapoptotic pathways, promoting cell survival. Akt also regulates the mammalian target of rapamycin (mTOR)-S6K-S6 pathway to control cell growth in response to growth factors and nutrients. Recent reports have shown that the… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
116 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 116 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…